You are here

Mini BMT Trial Data

Hi Sandy

I noticed in your reply below that you said the trial data was published in ASH 2006. I had read all the abstracts and posts about ASH I saw and don;t remember seeing this data - was it specific to the trial you took part in, i.e. Eduardo and Dr Craddock's? I had asked Eduardo in October whether the data or trial report was available yet and he said not so it must have been published for the 1st time at ASH?

Glad to have read about your recent results. It must be a great relief to have seen such a drop.

I havn;t been posting much recently although I read all the posts. After a few PCR bounces mid last year and moving towards the conclusion that 800mg Glivec was not working, the latest PCR results from both Dublin and HH both showed drops with HH's giving my lowest result to date...nearly a 3log reduction....which was pleasing. So the plan was to stay on 800mg and repeat the test in early 07...which has come about too quickly! I pretty sure Sprycel is approved here now although I need to check whether it has been approved in terms of funding it through the drug high tech scheme to allow it to be available at reasonable cost to patients...so if the need arises trying it should be an option now....but hopefully that won;t be the case and that the 800mg will be still doing the job.

Anyway, I'd be interesting in reading the trial data if available. If you can confirm that it was indeed the trial you were on I'll have a look over the ASH abstracts again and try and find it.

Thanks

Brian

hi brian,
yes i did mean the study i am part of. i am pretty sure eduardo said they were ready to publish before ASH... if you search under charles craddock et al hopefully you will find it.
if not i think they are hoping to get it published in New England Journal but i am not sure when. i am seeing eduardo on 18th of this month so i will ask him if it is available for us to read.

good news about your response to 800mg.. three log reduction is good news!
if your side effects to 800mg of glivec become a problem, you can always access nilotinib as unlike dasatinib it is in trial and as you know dublin is open. reports of responses in phase ll trials are impressive i hear, although i have no detail as yet.

let me know if you find the craddock/olaviarra study data.... i too would love to read it.
best wishes,
sandy C ;o)